Filing Overview
This Form 6-K was filed by I-MAB, a foreign private issuer, for December 2021 and dated December 10, 2021. The provided metadata identifies the company as Novabridge Biosciences, but the filing itself identifies the registrant as I-MAB. The filing reports changes to the Board of Directors and Audit Committee.
Business Context and Reporting Period
I-MAB is headquartered in Shanghai, China, and files annual reports on Form 20-F. The filing does not provide operating or financial results for a reporting period.
Financial and Operating Metrics
- Revenue, profit, cash flow, margins, debt, liquidity, and other financial metrics: not provided in the filing text.
- No financial guidance or quantitative operating outlook is disclosed.
Material Changes and Management Commentary
- John Long, who joined I-MAB as Chief Financial Officer in November 2021, was appointed to the Board effective December 10, 2021.
- John Long replaced Yu Jie, the board representative of Tasly, who resigned on the same day.
- Liu Xi was appointed to the Board and Audit Committee effective December 10, 2021.
- Liu Xi replaced Yuan Bing of Hony Capital, who resigned on the same day.
- The Board determined that Liu Xi satisfies Nasdaq independence requirements under Rule 5605(c)(2) and the audit committee independence standards under Exchange Act Rule 10A-3.
- Both new directors entered into the company’s standard indemnification agreement.
- John Long oversees global finance, capital markets activities including dual-listing efforts, investor relations, and financial management.
Risks, Contingencies, and Unusual Items
The filing does not disclose material contingencies, litigation, financial risks, unusual accounting items, or changes to business guidance. The board and committee membership changes may be relevant to governance, capital markets execution, and oversight of financial reporting.
Investor Verification Checklist
- Confirm the correct registrant, since the filing names I-MAB rather than Novabridge Biosciences.
- Verify the effective dates and replacement of the four directors identified in the filing.
- Review Liu Xi’s independence status under applicable Nasdaq and Exchange Act requirements.
- Assess the implications of the CFO’s Board appointment for financial oversight and the stated dual-listing efforts.
- Consult I-MAB’s periodic financial filings for revenue, cash, liquidity, debt, clinical-program funding, and other financial information not included in this Form 6-K.